Generic Name and Formulations:
Natamycin 5%; oph susp; contains benzalkonium chloride 0.02%.
Alcon Laboratories, Inc.
Indications for NATACYN:
Treatment of fungal blepharitis, conjunctivitis, and keratitis due to susceptible organisms including Fusarium solani keratitis.
Keratitis: initially 1 drop in the conjunctival sac at hourly or two-hourly intervals. May reduce to 1 drop 6–8 times daily after the first 3–4 days. Continue for 14–21 days or until resolution. Reduce dose gradually at 4–7 day intervals to assure replicating organism is eliminated. Blepharitis, conjunctivitis: less frequent initial dosage (4–6 daily applications) may be sufficient.
Reevaluate if no improvement after 7–10 days. Monitor at least twice weekly; discontinue if drug toxicity occurs. Pregnancy (Cat. C). Nursing mothers.
Conjunctival chemosis and hyperemia.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Encorafenib, Binimetinib Combination Receives FDA Approval for Mutation-Positive Melanoma
- Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Patient Interest in Melanoma Genetic Risk Testing is Fairly High
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Bleeding Disorder Treatments: Hemophilia A
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|